Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 01, 2021 08:00 ET | Source: Caelum Biosciences, Inc.

Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month

BORDENTOWN, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases, today...
December 04, 2018 08:00 ET | Source: Caelum Biosciences, Inc.

Caelum Biosciences Announces Two Oral Presentations of Additional Data from Phase 1b Study of Anti-Amyloid mAb CAEL-101 and Preclinical Imaging Study at 60th American Society of Hematology Annual Meeting

Phase 1b data confirm efficacy in AL Amyloidosis with two cardiac markers correlated with survival Preclinical data demonstrate the potential of using radiolabeled CAEL-101 for real-time imaging of...
November 02, 2018 08:00 ET | Source: Caelum Biosciences, Inc.

Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentations at 60th American Society of Hematology Annual Meeting

NEW YORK, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a company focused on developing treatments for rare and life-threatening diseases, today announced that additional...
June 25, 2018 07:30 ET | Source: Caelum Biosciences, Inc.

Caelum Biosciences Announces Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis

Nine of 10 cardiac patients on CAEL-101 showed improvement in global longitudinal strain CAEL-101 led to sustained decrease in NT-proBNP levels Data presented at American Society of Echocardiography...
June 18, 2018 07:30 ET | Source: Caelum Biosciences, Inc.

Caelum Biosciences Announces Presentation of Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis at American Society of Echocardiography 29th Annual Scientific Sessions

NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company developing treatments for rare and life-threatening diseases, today...
April 20, 2018 22:00 ET | Source: Caelum Biosciences, Inc.

Caelum Biosciences Submits Draft Registration Statement on Form S-1 to the Securities and Exchange Commission

NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. Company developing treatments for rare and life-threatening diseases, today announced it...
March 27, 2018 08:00 ET | Source: Caelum Biosciences, Inc.

Caelum Biosciences Announces Updated Phase 1b Data Presented at 16th International Symposium on Amyloidosis

NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company developing treatments for rare and life-threatening diseases, today...
March 21, 2018 08:00 ET | Source: Caelum Biosciences, Inc.

Caelum Biosciences Announces Clinical Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 16th International Symposium on Amyloidosis

NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company developing treatments for rare and life-threatening diseases, today...
December 11, 2017 08:00 ET | Source: Caelum Biosciences, Inc.

Caelum Biosciences Announces Positive Phase 1a/1b Data Demonstrating CAEL-101 (mAb 11-1F4) Improves Organ Function in AL Amyloidosis

Eight of 12 patients (67 percent) with cardiac involvement responded to therapy with a median time to cardiac response of 21 days 14 of 24 (63 percent) of patients demonstrated organ response ...
November 01, 2017 09:05 ET | Source: Caelum Biosciences, Inc.

Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting

NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company focused on developing treatments for rare and life-threatening...